BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30686699)

  • 1. Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial.
    Van Herck A; Frick AE; Schaevers V; Vranckx A; Verbeken EK; Vanaudenaerde BM; Sacreas A; Heigl T; Neyrinck AP; Van Raemdonck D; Dupont LJ; Yserbyt J; Verleden SE; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Mar; 38(3):252-259. PubMed ID: 30686699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin prophylaxis after lung transplantation is associated with improved overall survival.
    Li D; Duan Q; Weinkauf J; Kapasi A; Varughese R; Hirji A; Lien D; Meyer S; Laing B; Nagendran J; Halloran K
    J Heart Lung Transplant; 2020 Dec; 39(12):1426-1434. PubMed ID: 33041181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
    Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Vanaudenaerde BM; Somers J; Schoonis A; Schaevers V; Van Raemdonck DE; Neyrinck A; Dupont LJ; Yserbyt J; Verleden GM; Vos R
    Am J Transplant; 2016 Jan; 16(1):254-61. PubMed ID: 26372728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of azithromycin and allograft rejection on the post-lung transplant microbiota.
    Spence CD; Vanaudenaerde B; Einarsson GG; Mcdonough J; Lee AJ; Johnston E; Verleden GM; Elborn JS; Dupont LJ; Van Herck A; Gilpin DF; Vos R; Tunney MM; Verleden SE
    J Heart Lung Transplant; 2020 Feb; 39(2):176-183. PubMed ID: 31812487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.
    Vos R; Vanaudenaerde BM; Verleden SE; De Vleeschauwer SI; Willems-Widyastuti A; Van Raemdonck DE; Schoonis A; Nawrot TS; Dupont LJ; Verleden GM
    Eur Respir J; 2011 Jan; 37(1):164-72. PubMed ID: 20562124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection.
    Vos R; Vanaudenaerde BM; Verleden SE; Ruttens D; Vaneylen A; Van Raemdonck DE; Dupont LJ; Verleden GM
    Transplantation; 2012 Jul; 94(2):101-9. PubMed ID: 22461039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.
    Vandermeulen E; Verleden SE; Ruttens D; Moelants E; Mortier A; Somers J; Bellon H; Piloni D; Dupont LJ; Van Raemdonck DE; Proost P; Schols D; Vos R; Verleden GM; Vanaudenaerde BM
    Transpl Immunol; 2015 Sep; 33(1):37-44. PubMed ID: 26168736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a post-transplant chronic lung allograft dysfunction classification system.
    Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
    J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast in chronic lung allograft dysfunction after lung transplantation.
    Vos R; Eynde RV; Ruttens D; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck DE; Verleden GM;
    J Heart Lung Transplant; 2019 May; 38(5):516-527. PubMed ID: 30638839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.
    Greer M; Dierich M; De Wall C; Suhling H; Rademacher J; Welte T; Haverich A; Warnecke G; Ivanyi P; Buchholz S; Gottlieb J; Fuehner T
    Am J Transplant; 2013 Apr; 13(4):911-918. PubMed ID: 23406373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Recipients with Chronic Rejection.
    Combs MP; Luth JE; Falkowski NR; Wheeler DS; Walker NM; Erb-Downward JR; Wakeam E; Sjoding MW; Dunlap DG; Admon AJ; Dickson RP; Lama VN
    Am J Respir Crit Care Med; 2024 Jun; 209(11):1360-1375. PubMed ID: 38271553
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung Density Analysis Using Quantitative Chest CT for Early Prediction of Chronic Lung Allograft Dysfunction.
    Horie M; Levy L; Houbois C; Salazar P; Saito T; Pakkal M; OʼBrien C; Sajja S; Brock K; Yasufuku K; Keshavjee S; Paul N; Martinu T
    Transplantation; 2019 Dec; 103(12):2645-2653. PubMed ID: 31343572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose vitamin D after lung transplantation: A randomized trial.
    Vos R; Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Van Herck A; Sacreas A; Heigl T; Schaevers V; Van Raemdonck DE; Verbeken EK; Neyrinck AP; Dupont LJ; Yserbyt J; Vanaudenaerde BM; Verleden GM
    J Heart Lung Transplant; 2017 Aug; 36(8):897-905. PubMed ID: 28365177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study.
    Testaert H; Bouet M; Valour F; Gigandon A; Lafon ME; Philit F; Sénéchal A; Casalegno JS; Blanchard E; Le Pavec J; Ader F
    Clin Microbiol Infect; 2021 Jun; 27(6):897-903. PubMed ID: 32827713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.
    Ruttens D; Verleden SE; Demeyer H; Van Raemdonck DE; Yserbyt J; Dupont LJ; Vanaudenaerde BM; Vos R; Verleden GM
    PLoS One; 2018; 13(4):e0193564. PubMed ID: 29624575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.
    Kapnadak SG; Morrell ED; Wai TH; Goss CH; Shah PD; Merlo CA; Hachem RR; Ramos KJ
    J Heart Lung Transplant; 2022 Jan; 41(1):20-23. PubMed ID: 34785136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.
    Gautschi F; Vogelmann T; Ortmanns G; Knörr F; Steinack C; Hage R; Nägeli M; Schuurmans MM
    J Clin Apher; 2024 Jun; 39(3):e22128. PubMed ID: 38829041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation.
    Vos R; Verleden SE; Ruttens D; Vandermeulen E; Bellon H; Neyrinck A; Van Raemdonck DE; Yserbyt J; Dupont LJ; Verbeken EK; Moelants E; Mortier A; Proost P; Schols D; Cox B; Verleden GM; Vanaudenaerde BM
    Am J Transplant; 2014 Dec; 14(12):2736-48. PubMed ID: 25394537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of CT-SCAN score and volume measures to early identify restrictive allograft syndrome in single lung transplant recipients.
    Philippot Q; Debray MP; Bun R; Frija-Masson J; Bunel V; Morer L; Roux A; Picard C; Jebrak G; Dauriat G; Castier Y; Cazes A; Mal H; Taupin JL; Couffignal C; Brugière O
    J Heart Lung Transplant; 2020 Feb; 39(2):125-133. PubMed ID: 31836403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.
    Todd JL; Neely ML; Finlen Copeland CA; Frankel CW; Reynolds JM; Palmer SM
    J Heart Lung Transplant; 2019 Feb; 38(2):184-193. PubMed ID: 30466803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.